Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Misonix, Inc.    MSON

MISONIX, INC.

(MSON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Misonix : SonicVac™ Recognized as a Top Innovation for Wound Care in Podiatry

share with twitter share with LinkedIn share with facebook
07/12/2016 | 10:23am EDT

FARMINGDALE, N.Y., July 12, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced its recently launched product, SonicVac™, has been recognized by Podiatry Today as one of the 'Top 10 Innovations in Podiatry for 2016.' Podiatry Today, an award-winning publication devoted to practicing podiatric professionals, lists the SonicVac in their July edition as an innovation that can spur wounds toward healing with the unique combination of ultrasound and aspiration.

SonicVac is the latest addition to the SonicOne platform that combines the advantages of vacuum aspiration with the precision and power of Low Frequency Direct Contact Ultrasound (LFDCU) debridement. From data released at the 2016 Spring Diabetic Limb Salvage Conference, this combination has shown that SonicVac increased the removal of potentially infected irrigant and debris from the treatment area by 134% over ultrasound alone.

Dr. Lee Rogers, Medical Director, Amputation Prevention Centers of America, said, 'SonicOne with SonicVac allows the surgeon to selectively debride from the superficial to deep tissue while containing the spread of air-transmitted infectious matter from the surgeon and the O.R. staff. The ability that this innovative product can provide safety for the patient and the user while potentially promoting healthy tissue regeneration for chronic wounds post debridement, positions SonicOne as the standard of advanced wound care.'

'The combination of ultrasound and aspiration in the SonicVac is both innovative and important in treating patients with chronically infected wounds. Our data indicates the containment and removal of bioburden from the wound site is a significant improvement over existing debridement approaches,' said Dr. Mark S. Granick, Professor and Chief, Division of Plastic Surgery, Rutgers, New Jersey Medical School. 'The Podiatry Today Innovation recognition is timely given the focus by hospitals on infection control, decreasing length of stay and healing difficult chronic wounds. The SonicVac's unique characteristics can enable podiatrists to improve outcomes in all of these areas.'

'This recent acknowledgement by Podiatry Today validates the hard work that our team has done to develop solutions that can significantly enhance treatment and improve patient outcomes,' remarked Scott Ludecker, Misonix Senior Vice President of Global Sales and Marketing. 'We have developed a growing portfolio of innovative medical devices that address unmet clinical needs in the marketplace, both domestically and internationally.'

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, 'The recognition by Podiatry Today and the wide acceptance by wound experts of SonicVac further reinforces our focus in developing products that address needs in the wound space with advanced and innovative designs. We're honored to be recognized this year as a Top 10 innovation.'

The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process.

The SonicOne with SonicVac procedure will be sold and distributed through the Misonix sales team and its distributor network in the United States and worldwide.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain 'forward looking statements' that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/misonix-sonicvac-recognized-as-a-top-innovation-for-wound-care-in-podiatry-300297279.html

SOURCE Misonix, Inc.

Misonix Inc. published this content on 12 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 July 2016 14:23:03 UTC.

share with twitter share with LinkedIn share with facebook
Latest news on MISONIX, INC.
07/01MISONIX INC : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
07/01MISONIX INC : Change in Directors or Principal Officers, Submission of Matters t..
AQ
05/22Misonix to Present at the 17th Annual Craig Hallum Institutional Investor Con..
GL
05/11MISONIX : Fiscal 3Q Earnings Snapshot
AQ
05/11MISONIX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/11Misonix Fiscal 2020 Third Quarter Revenue Rises to $17.9 Million
GL
05/11MISONIX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
05/06Misonix to Report Fiscal 2020 Third Quarter Financial Results and Host Confer..
GL
04/15MISONIX INC : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
04/02MISONIX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
More news
Financials (USD)
Sales 2020 56,9 M - -
Net income 2020 -18,1 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,9x
Yield 2020 -
Capitalization 231 M 231 M -
EV / Sales 2019
Capi. / Sales 2020 4,06x
Nbr of Employees 125
Free-Float 78,3%
Chart MISONIX, INC.
Duration : Period :
Misonix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MISONIX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 19,33 $
Last Close Price 13,32 $
Spread / Highest target 65,2%
Spread / Average Target 45,1%
Spread / Lowest Target 35,1%
EPS Revisions
Managers
NameTitle
Stavros G. Vizirgianakis Chief Executive Officer & Director
Allan R. Staley President
Paul Arthur LaViolette Chairman
Sharon W. Klugewicz Chief Operating Officer
Joseph P. Dwyer Chief Financial Officer, Secretary & Treasurer
Sector and Competitors
1st jan.Capitalization (M$)
MISONIX, INC.-28.43%231
ABBOTT LABORATORIES7.03%164 450
MASIMO CORPORATION48.42%12 695
ASAHI INTECC CO., LTD.-3.91%7 453
NOVOCURE LIMITED-25.41%6 314
GETINGE AB3.56%5 296